Solid Tumor
Conditions
Brief summary
This study aims to screen tumor molecular profile for better selection of anticancer treatment, in particular, allocation to clinical trials if available.
Detailed description
Molecular profiling will be performed on archival tumor tissue or freshly collected tumor tissue from re-biopsy. Blood, pleural fluid, FNA, and/or saliva may be collected to study the genetic makeup and also to compare the tumor molecular profile. Personalized therapy will be given based on molecular profile.
Interventions
None listed
Sponsors
National Cancer Centre, Singapore
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Confirmed histological diagnosis of solid tumor * Suitable for systematic treatment and clinical trials * ECOG (Eastern cooperative oncology group) performance status \< 2 * Able to provide tumor tissue for molecular profiling * Able to understand and sign the informed consent form
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The molecular and clinical epidemiology for cancer patients being considered for novel therapeutics | 5 years |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of patients who have actionable alterations and enrol into clinical trials | 5 years |
| The correlation of molecular profiles with clinical outcomes | 5 years |
Countries
Singapore
Contacts
CONTACTDaniel SW Tan
PRINCIPAL_INVESTIGATORDaniel SW Tan
National Cancer Centre, Singapore
Outcome results
None listed